In this large retrospective cohort study, we found that GLP-1 RAs were associated with significantly lower CV risk in patients with type 2 diabetes and BMI 25 or more compared with matched patients using DPP-4 inhibitors. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.